ZYME - Zymeworks Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
24.90
-0.60 (-2.37%)
As of 10:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close25.50
Open25.00
Bid24.82 x 900
Ask25.04 x 800
Day's Range24.78 - 25.32
52 Week Range10.72 - 27.19
Volume36,117
Avg. Volume280,793
Market Cap978.07M
Beta (3Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates

    Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Zymeworks Reports 2019 Second Quarter Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

  • Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks

    Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zymeworks' Shares March Higher, Can It Continue?
    Zacks

    Zymeworks' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Zymeworks.

  • Business Wire

    Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the companies’ 2014 Azymetric™ collaboration and licensing agreement. Zymeworks’ proprietary Azymetric technology platform enables the rapid development of bispecific and multifunctional therapeutics with broad potential for the treatment of cancer, inflammation, and infectious disease. Zymeworks will receive a US$7.5 million payment as a result of Celgene’s exercise of its option to a commercial license.

  • Red Hot Stocks Ahead of G20 Summit
    Zacks

    Red Hot Stocks Ahead of G20 Summit

    Red Hot Stocks Ahead of G20 Summit

  • Will Zymeworks Continue to Surge Higher?
    Zacks

    Will Zymeworks Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Zymeworks.

  • Business Wire

    Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares

    Zymeworks Inc. , a clinical stage biopharmaceutical company developing multifunctional biotherapeutics , announced today the closing of its previously announced underwritten public offering .

  • Business Wire

    Zymeworks Announces Pricing of $175.0 Million Public Offering

    Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 5,555,556 common shares and, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares. The common shares are being offered at a price to the public of US$18.00 per common share and the pre-funded warrants are being offered at a price of US$17.9999 per pre-funded warrant, for aggregate gross proceeds to the Company of approximately US$175.0 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Company has also granted the underwriters of the Offering a 30-day over-allotment option to purchase up to an additional 1,458,336 common shares on the same terms and conditions.

  • Business Wire

    Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Canadian Supplement”) to its Canadian short form base shelf prospectus dated March 6, 2019 (the “Base Prospectus”) in connection with an offering of its common shares and pre-funded warrants to purchase its common shares (the “Offering”). The Canadian Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Canada. A preliminary prospectus supplement (the “U.S. Supplement,” together with the Canadian Supplement, the “Supplements”) was also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration statement on Form S-3, as amended, including a prospectus which became effective January 31, 2019 (the “Registration Statement”), pursuant to which the securities will be offered in the United States.

  • Business Wire

    Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY.

  • Business Wire

    Zymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of two new independent members to its Board of Directors, further enhancing the Board’s commercial expertise. The new board members are Sue Mahony, Ph.D., MBA, a pharmaceutical executive with over 30 years of combined experience with Eli Lilly and Company (Lilly), Schering-Plough, Amgen, and Bristol-Myers Squibb, and Troy Cox, MBA, who has served in numerous senior leadership positions at leading biopharmaceutical companies such as Foundation Medicine, Roche-Genentech, UCB BioPharma, Sanofi-Aventis, and Schering-Plough.

  • Benzinga

    The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...

  • Business Wire

    Zymeworks' Lead Asset, ZW25, Granted Fast Track Designation from the FDA

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW25, a novel Azymetric™ bispecific antibody, for the first-line treatment of patients with HER2-overexpressing gastroesophageal adenocarcinoma in combination with standard of care chemotherapy. “Receipt of Fast Track designation from the FDA emphasizes the large unmet need of patients with these types of HER2-expressing cancers,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO.

  • Business Wire

    Zymeworks Earns Milestone Payment in Merck Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has earned a milestone payment from Merck (known as MSD outside the US and Canada) achieved under the companies’ 2014 research and license agreement. Zymeworks will receive US$2.0 million in connection with Merck’s completion of a late-stage preclinical study for a bispecific antibody candidate using Zymeworks’ proprietary Azymetric™ and EFECT™ therapeutic platforms. “Merck’s completion of this milestone is great news,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks.

  • Business Wire

    Zymeworks to Present at Jefferies 2019 Global Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY.

  • Business Wire

    Zymeworks Announces Corporate Update Conference Call

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.

  • Business Wire

    Zymeworks and GSK Expand 2016 Azymetric™ Bispecific Agreement

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.

  • Business Wire

    Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer. “We believe this first ZymeLink licensing deal provides further validation of our novel ADC technology, which is already being used in Zymeworks’ own clinical candidate, ZW49,” said Ali Tehrani, Ph.D., President and Chief Executive Officer of Zymeworks. “Historically, traditional ADC development has been plagued by a number of challenges related to toxicity and efficacy.

  • Business Wire

    Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 2, 2019 .

  • Business Wire

    Zymeworks Reports 2019 First Quarter Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019.

  • Business Wire

    Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and ...

  • Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
    Business Wire

    Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform

    VANCOUVER, British Columbia VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.-- -- One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ...

  • Business Wire

    Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co.

  • Business Wire

    Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas. “Advancing ZW25 into a Phase 2 clinical trial represents another key milestone for Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “This reaffirms our commitment to execute our ambitious drug development strategy to address unmet need in patients with HER2-expressing cancers across multiple indications and lines of therapy.